ustekinumab

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:administered_by subcutaneous injection
gptkbp:approves gptkb:2009
gptkb:FDA
gptkbp:biologic_class Ig G1 kappa monoclonal antibody
gptkbp:chemical_formula C_45 H_69 N_13 O_13 S
gptkbp:clinical_trial Phase 3
gptkbp:clinical_use chronic inflammatory conditions
gptkbp:contraindication active infections
hypersensitivity to the drug
gptkbp:developed_by gptkb:Janssen_Pharmaceuticals
gptkbp:drug_interactions immunosuppressants
live vaccines
gptkbp:excretion primarily through the reticuloendothelial system
gptkbp:financial_stability stable for 24 hours at room temperature after reconstitution
gptkbp:formulation lyophilized powder for injection
https://www.w3.org/2000/01/rdf-schema#label ustekinumab
gptkbp:indication gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis
gptkbp:invention 2028
gptkbp:is_monitored_by monitor for allergic reactions
monitor for signs of infection
gptkbp:lifespan 15 to 46 days
gptkbp:marketed_as gptkb:Stelara
gptkbp:mechanism_of_action inhibits IL-12 and IL-23
gptkbp:patient_education advise on potential side effects
importance of follow-up appointments
instruct on proper injection technique
gptkbp:provides_guidance_on recommended for moderate to severe cases
gptkbp:recommissioned requires sterile water for injection
gptkbp:research_areas gptkb:disease
autoimmune diseases
rheumatology
dermatology
gptkbp:route_of_administration subcutaneous
gptkbp:service_frequency every 12 weeks after initial dose
gptkbp:side_effect fatigue
headache
nausea
rash
increased risk of infections
injection site reactions
thrombocytopenia
hypersensitivity reactions
elevated liver enzymes
gptkbp:storage refrigerated
gptkbp:targets gptkb:interleukin-23
interleukin-12
gptkbp:used_for treatment of psoriasis
treatment of ulcerative colitis
treatment of Crohn's disease
gptkbp:website abdomen or thigh
gptkbp:weight 150 k Da
gptkbp:bfsParent gptkb:Stelara
gptkbp:bfsLayer 5